Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)
NCT05594433 · CellProthera · PHASE1 · terminated · last registry update 2026-10-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Strategic change” | – | Registry record, CellProthera |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF3R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Zilovertamab vedotin (NCT07917754)
- 2026-10-23Results posted on the registry: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2026-10-22Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Carboplatin (NCT03036488)
- 2026-10-21Also stopped (terminated): Medical College of Wisconsin, Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen + Cladribine and Cytarabine (CLLDAC) Regimen (NCT03150004)
- 2026-09-30Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, rhTPO prophylaxis plus EAP stem-cell mobilization (NCT07848672)
- 2026-09-29Also stopped (suspended): University of Washington, Asparaginase Erwinia chrysanthemi + Cyclophosphamide (NCT06738368)
- 2026-09-21Phase 3 first posted: Merck Sharp & Dohme LLC, Sac-TMT + Pembrolizumab and Berahyaluronidase alfa (NCT07829783)
- 2026-08-24Also stopped (terminated): University of Michigan Rogel Cancer Center, Venetoclax + FLAG or CLAG Protocol (NCT05780879)
- 2026-08-20Results posted on the registry: Trio Fertility, Neupogen (NCT06117982)
- 2026-07-29Phase 3 first posted: Ruijin Hospital, Mitoxantrone Hydrochloride Liposome + Cytarabine (NCT07735117)
- 2026-07-09Phase 3 first posted: First Affiliated Hospital of Zhejiang University, Single-dose Granulocyte colony-stimulating factor (G-CSF) + Divided-dose Granulocyte colony-stimulating factor (G-CSF) (NCT07692841)
- 2026-07-09Phase 3 first posted: Nanjing University, Granulocyte Colony-Stimulating Factor(G-CSF) + Normal Saline (NCT07692672)
- 2026-06-29Results posted on the registry: St. Jude Children's Research Hospital, vincristine + topotecan (NCT01783535)
- 2026-06-24Results posted on the registry: Columbia University, Brentuximab Vedotin + Bendamustine (NCT01657331)
- 2026-06-24Also stopped (terminated): National Cancer Institute (NCI), Bevacizumab + Docetaxel (NCT01012297)
- 2026-06-01Results posted on the registry: Washington University School of Medicine, Tacrolimus + Mycophenolate mofetil (NCT02782546)
- 2026-06-01Also stopped (terminated): Northwestern University, Cytarabine + Filgrastim (NCT04250051)
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-14Results posted on the registry: Fred Hutchinson Cancer Center, Liposome-encapsulated Daunorubicin-Cytarabine + Cladribine (NCT04195945)
- 2026-05-07Also stopped (withdrawn): M.D. Anderson Cancer Center, Fludarabine + Cytarabine (NCT07428486)
- 2026-04-29Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Briquilimab + Filgrastim (NCT06145282)
- 2026-04-24Also stopped (terminated): European Society for Blood and Marrow Transplantation, G-CSF + Early retreatment with ATG (NCT01163942)
- 2026-04-21Phase 3 first posted: Fujian Medical University Union Hospital, PD-1 Inhibitors (NCT07541755)
- 2026-04-16Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Polatuzumab vedotin (PV) + Rituximab (NCT05498220)
- 2026-04-16Also stopped (terminated): UNC Lineberger Comprehensive Cancer Center, Polatuzumab vedotin (PV) + Rituximab (NCT05498220)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision